Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer Studies Herbicide Shift As It Looks Beyond Roundup -- WSJ

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/17/2019 | 02:48am EDT

By Ruth Bender and Jacob Bunge

Bayer AG plans to invest EUR5 billion ($5.64 billion) on developing new ways to combat weeds over the next decade, as the German chemicals and pharmaceuticals giant seeks to win back trust in its business in the wake of thousands of lawsuits alleging its Roundup herbicide causes cancer.

A big legal fight over the blockbuster weedkiller -- inherited with its takeover of Monsanto Co. last year -- has plunged Bayer into one of the worst crises in its 155-year history. The company has lost the first three jury trials to plaintiffs claiming Roundup gave them non-Hodgkin lymphoma, with the highest award topping $2 billion. In response, its shares have almost halved over the past year.

While Bayer is appealing the jury verdicts and continues to vigorously defend the safety of Roundup and the active ingredient glyphosate, its announcement Friday shows how the company is being forced to change tack under pressure from its legal woes. Bayer said glyphosate would retain an important role in its portfolio but that it was also "committed to offering more choice for growers."

The company said the EUR5 billion earmarked for herbicide development over the next 10 years would largely fit into the annual spending of EUR2.4 billion that it had previously estimated for agriculture R&D in coming years. Herbicide research will represent about one-fifth of Bayer's overall agriculture research investment, and the commitment announced Friday will include chemical research and regulatory expenses as well as new computer-driven farm-management services.

The company also said it would cut its "environmental impact" by 30% by 2030 through new technologies and making weedkiller use more precise, and that it would also be more transparent about the safety of its products. These measures, it said, would address health and environmental concerns Bayer has faced since buying Monsanto. Bayer also took out newspaper advertisements to promote its message.

The company's leadership has faced intense criticism over its decision to buy Monsanto. At a heated shareholder meeting in late April, some 55% of shareholders refused to endorse management's actions in the past year.

Bayer and other agricultural companies are already marketing new herbicides, as glyphosate's widespread use on U.S. farms has contributed to weeds like palmer amaranth and waterhemp developing resistance to the world's most widely used weedkiller.

Bayer said Friday that with glyphosate's global success came "widespread use, weed resistance, and in some instances unintended misapplication."

Monsanto in recent years launched a new herbicide based on the chemical dicamba, along with soybean and cotton seeds genetically engineered to withstand the spray.

Some farmers have said the more-powerful weedkiller drifted onto neighboring fields and damaged nonmodified crops. Agricultural researchers estimate that millions of acres of crops have been damaged by drifting dicamba. Bayer has attributed the crop damage mainly to farmers misapplying the spray. In 2018 the U.S. Environmental Protection Agency said farmers could continue to use dicamba under tighter restrictions.

Rival Corteva Inc. is marketing a competing crop seed and herbicide combination, based around the herbicide 2,4-D.

The legal battle over Roundup could take years to resolve as Bayer has said it would appeal decisions and wait for the outcome of a few more cases before considering a settlement.

Investors say Bayer's stock is likely to struggle until there is more clarity over how much the litigation will end up costing the company. Analysts' estimates range from EUR5 billion to EUR25 billion.

In 2015 the International Agency for Research on Cancer, a World Health Organization unit, classified glyphosate as likely having the potential to cause cancer in humans. That classification triggered the wave of lawsuits. Bayer argues hundreds of studies and regulatory decisions around the world show Roundup and glyphosate are safe when used as directed.

In the U.S., where Roundup has become integral to farming, Costco Wholesale Corp. recently pulled Roundup herbicides from its stores. Certain cities in California, Florida, Minnesota and elsewhere have also forbidden use of glyphosate weedkillers on municipal property while other farm-state lawmakers have defended the herbicides.

Several European countries, including France and Austria, are considering phasing out glyphosate. Early this year, a French court banned a Roundup product with the ingredient, even though it still has a European Union seal of approval. A senior executive of German public rail operator Deutsche Bahn AG told a German weekly Friday that the company together with the German environment ministry would research alternatives for combating weeds along its 33,000 kilometers of tracks.

The company said it would invite scientists, journalists and representatives from nonprofits to participate in its efforts to secure re-registration of glyphosate in the EU -- a review likely to trigger debate about safety. The process is expected to kick off later this year, with a vote in late 2022.

--Cristina Roca contributed to this article.

Write to Ruth Bender at Ruth.Bender@wsj.com and Jacob Bunge at jacob.bunge@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG 0.34% 59.89 Delayed Quote.-1.67%
NEW YORK COTTON 2.42% 62.25 End-of-day quote.-13.90%
SOYBEAN OIL FUTURES (ZL) - CBE (ELECTRONIC)/C1 1.99% 28.19 End-of-day quote.0.47%
SOYBEANS FUTURES (S) - CBR (FLOOR)/C1 2.30% 901.5 End-of-day quote.-0.14%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
06:52aBAYER COULD BENEFIT FROM HOME ADVANT : experts
RE
04:27aBAYER : Drug Iberogast Under Investigation -Handelsblatt
DJ
07/19BAYER : Syngenta profits hit by U.S./China trade wars, bad weather
RE
07/19BAYER : welcomes judge's call for reduced damages in $2 billion glyphosate case
RE
07/19BAYER : Correction to Bayer Verdict Article
DJ
07/19Does renewables pioneer Germany risk running out of power?
RE
07/19BAYER : Judge Cuts Third Bayer Roundup Verdict in Tentative Ruling
DJ
07/17BAYER : Leads Investment in U.S. Oncology Startup
DJ
07/17Activist hedge fund Elliott takes stake in UK's Saga
RE
07/16GRAIN HIGHLIGHTS : Top Stories of the Day
DJ
More news
Financials (EUR)
Sales 2019 46 326 M
EBIT 2019 8 877 M
Net income 2019 3 589 M
Debt 2019 37 542 M
Yield 2019 4,80%
P/E ratio 2019 17,0x
P/E ratio 2020 12,4x
EV / Sales2019 2,01x
EV / Sales2020 1,90x
Capitalization 55 496 M
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 77,90  €
Last Close Price 59,51  €
Spread / Highest target 107%
Spread / Average Target 30,9%
Spread / Lowest Target -34,9%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-1.67%62 271
JOHNSON & JOHNSON0.98%345 980
PFIZER-2.02%237 451
ROCHE HOLDING LTD.8.73%230 263
ROCHE HOLDING10.69%230 263
NOVARTIS24.78%216 273